Skip to main content

Search articles in

Found 3,024 articles

  • New dual therapeutic strategy shows promise agains

    New dual therapeutic strategy shows promise against multidrug-resistant salmonella

    • 7 Mar 2024
    • Editor

    A new collaborative study discloses the discovery and application of a new therapeutic strategy to target the multidrug-resistant bacterium Salmonella enterica in vivo, with promising results. The results were published in Scientific Reports.

  • Top Ten Recruiters Hiring in March 2024

    Top Ten Recruiters Hiring in March 2024

    • 7 Mar 2024
    • Nola Cadman

    Here are the top Pharma and Life Science recruitment organisations advertising in March 2024 on PharmiWeb.jobs

  • About Almac Group

    About Almac Group

    • 7 Mar 2024
    • Editor

    The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.

  • Zenas BioPharma Appoints Patricia Allen to its Boa

    Zenas BioPharma Appoints Patricia Allen to its Board of Directors

    • 7 Mar 2024
    • Editor

    Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology-directed therapies, today announced the appointment of Patricia Allen to its Board of Directors, on which she also will serve as Chairperson of the Audit Committee.

  • Average UK Clinical Research Salaries in 2024

    Average UK Clinical Research Salaries in 2024

    • 7 Mar 2024
    • Lucy Walters

    The UK government is currently on a mission to make the UK one of the best places in the world to conduct clinical trials. Throughout 2024 and 2025, the government will be implementing recommendations made by Lord O’Shaughnessy in his 2023 independent review of UK commercial clinical trials to make this happen.

  • Top Ten Companies Hiring in March

    Top Ten Companies Hiring in March 2024

    • 6 Mar 2024
    • Nola Cadman

    Here's a list of the top pharma and life science companies hiring in March on PharmiWeb.jobs

  • About iTeos Therapeutics

    About iTeos Therapeutics

    • 6 Mar 2024
    • PharmiWeb Editor

    iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer.

  • iTeos Appoints Oncology Veteran Jill DeSimone to I

    iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

    • 6 Mar 2024
    • PharmiWeb Editor

    iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of Jill DeSimone to its Board of Directors...

  • Lantern Pharma's A.I. Platform, RADR®, Surpasses 6

    Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines

    • 6 Mar 2024
    • Editor

    The rapid growth of Lantern Pharma’s AI platform could lead to accelerated development of better treatments, greater precision in clinical development, and improved combination regimens with the potential for longer and more durable patient responses.

  • Transgene, NEC and BostonGene Expand Collaboration

    Transgene, NEC and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050

    • 6 Mar 2024
    • Editor

    Transgene, NEC Corporation, and BostonGene Corporation (BostonGene), a leading company in AI-based molecular and immune profiling, today announced the expansion of their collaboration for the randomized Phase I/II trial of TG4050, an individualized therapeutic vaccine for patients with head and neck cancers.

  • Ariceum Therapeutics announces opening of new stat

    Ariceum Therapeutics announces opening of new state-of-the-art laboratory in Berlin providing infrastructure for radiopharmaceutical development activities

    • 6 Mar 2024
    • Editor

    Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, is pleased to announce the opening of its new laboratory facilities on 7 March at its Berlin headquarters to house the research and development of its next generation radiopharmaceutical pipeline candidates and support the transfer of advancing products into the clinic.

  • Top 9 Clinical Research Organisations in 2024

    Top 9 Clinical Research Organisations in 2024

    • 6 Mar 2024
    • Lucy Walters

    In terms of revenue, the global clinical trials market was estimated to be worth $48.2 billion in 2023 and is expected to reach $73.2 billion by 2028, growing at a CAGR of 8.7%. In this article, we’ve rounded up 9 of the top Clinical Research Organisations (CROs) in the world, highlighting the key drivers of this growth.

  • About Coave Therapeutics

    About Coave Therapeutics

    • 6 Mar 2024
    • Editor

    At Coave Therapeutics, we are leading the transition of genetic medicine from rare to prevalent conditions, starting with neurodegenerative and eye diseases. Our proprietary ALIGATER™ (Advanced Vectors-Ligand Conjugates) platform introduces chemical modifications onto AAV capsids or Lipid Nanoparticles (LNPs) to overcome the limitations of current vectors on efficacy, safety, and manufacturability.

  • Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates

    Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial

    • 6 Mar 2024
    • Editor

    Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today follows the decision to stop the trial early due to efficacy, which was announced on 10 October 2023, based on a recommendation from an Independent Data Monitoring Committee.

  • Roche and Alnylam report positive topline results

    Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care

    • 6 Mar 2024
    • Editor

    Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase II KARDIA-2 study [NCT05103332] of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension (high blood pressure) - the leading cause of cardiovascular disease worldwide1 - met its primary endpoint.

  • Immutep Announces First Clinical Data from 90mg Do

    Immutep Announces First Clinical Data from 90mg Dosing of Efti

    • 6 Mar 2024
    • Editor

    Immutep (Formerly known as Prima Biomed) Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces safety and initial efficacy data from the first ever 90mg dosing of eftilagimod alpha (efti) in combination with weekly paclitaxel in patients from the safety lead-in (N=6) of the AIPAC-003 Phase II/III trial.

  • 5 Clinical Research Recruitment Trends for 2024

    5 Clinical Research Recruitment Trends for 2024

    • 5 Mar 2024
    • Lucy Walters

    The global clinical trials market size was valued at USD 80.7 billion in 2023 and is projected to grow at a CAGR of 6.49% from 2024 to 2030. Despite this anticipated growth, the clinical research industry has faced huge challenges over the past year, largely driven by political and economic turbulence.

  • About Clinigen

    About Clinigen

    • 4 Mar 2024
    • Editor

    Clinigen is a global, specialist pharmaceutical services company focused on providing ethical access to medicines. Its mission is to accelerate access to medicines for patients​ in every corner of the globe.

  • About CurifyLabs

    About CurifyLabs

    • 1 Mar 2024
    • Editor

    CurifyLabs is a Finnish health tech company developing solutions for producing personalized medicines in hospitals and compounding pharmacies. CurifyLabs' automated on-demand manufacturing concept, “the Pharma Kit” and printable pharmaceutical inks, enable personalized mass customization of medicines, allowing patient safety and efficacy at a significantly lower cost. CurifyLabs was founded in 2021 by Charlotta Topelius and Niklas Sandler Topelius.

  • CurifyLabs announces Jamie Campbell as New Board C

    CurifyLabs announces Jamie Campbell as New Board Chair to Further Boost Growth and Expansion

    • 29 Feb 2024
    • Editor

    CurifyLabs, a leading health technology company providing automated solutions for producing personalized medicine, announces today the appointment of Jamie Campbell as the new Chair of the Board. This strategic appointment further strengthens CurifyLabs' position as the company continues growth in Europe and expansion to the North American market.